Hepatic Hemangiopericytoma/Solitary Fibrous Tumor: A Review of Our Current Understanding and Case Study

Journal of Gastrointestinal Surgery

Volumn 16, Issue 11, 2012, Pages 2170-2176

  Bokshan, Steven L ^a   Doyle, Majella ^a   Becker, Nils ^a   Nalbantoglu, ILKe ^a   Chapman, William C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869123830     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1947-x     Document Type: Article

References (35)

1. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006; 48: 3-12.
2. Wagner E. Das tuberkelähnliche Lymphadenom. Arch Heilk 1870; 11: 495-525.
3. Klemperer P, Rabin C B. Primary neoplasms of the pleura. Arch Pathol (Chic) 1931; 11: 385-412.
4. Stout A, Murray MR. Hemangiopericytomas: vascular tumors arising from Zimmerman's pericytes. Ann Surg 1942; 116: 26-33.
5. Enzinger FM, Smith BH. Hemangiopericytoma: an analysis of 106 cases. Hum Pathol 1976; 7: 61-82.
6. Burgess NA, Hudd C, Matthews N. Two cases of hemangiopericytoma. BJU 1993; 71: 238-239.
7. Qin Z, Chi Y, Ya-ting Q, Li-zhen W, Jia-wei Z, Zhi-yuan Z. Malignant hemangiopericytoma of the condyle. Journal of Craniofacial Surgery 2012; 23: 33-36.
8. Herve S, Abd Alsamad I, Beautru R, et al. Management of sinonasal hemangiopericytomas. Rhinology 1999; 37: 153-158.
9. Lawson EA, Zhang X, Crocker JT, Wang WL, Klibansk A. Hypoglycemia from IGF2 overexpression associated with activation of fetal promoters and loss of imprinting in a metastatic hemangiopericytoma. Journal of Clinical Endocrinology & Metabolism 2009; 94: 2226-2231.
10. Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Horm IGF Res 2006; 16: 211-216.
11. Krešimir P, Šime S, Vicko G, Aljoša M, Dino P, Nikola K, Zvonimir K, Josip L, Csaba D, Tomislav Č, Jasminka P. The expression and role of insulin-like growth factor II in malignant hemangiopericytomas. J Mol Med 1999; 77: 865-869.
12. Rutkowski MJ, Bloch O, Jian BJ, Chen C, Sughrue ME, Tihan T, Barani IJ, Berger MS, McDermott MW, Parsa AT. Management of recurrent intracranial hemangiopericytoma. Journal of Clinical Neuroscience 2011; 18: 1500-1504.
13. de Groot JWB, Rikhof B, van Doorn J, Bilo HJG, Alleman MA, Honkoop AH, van der Graaf WTA. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocrine-Related Cancer 2007; 14: 979-993.
14. Moulton T, Crenshaw T, Hao Y, Moosikasuwan J, Lin N, Dembitzer F, Hensle T, Weiss L, McMorrow L, Loew T, Kraus W, Gerald W, Tycko B. Epigenetic lesions at the H19 locus in Wilms' tumour patients. Nat Genet 1994; 7: 440-447.
15. Taniguchi T, Sullivan MJ, Ogawa O, Reeve AE. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. Proc Natl Acad Sci U S A 1995; 92: 2159-2163.
16. Reeve AE, Eccles MR, Wilkins RJ, Bell GI, Millow LJ. Expression of insulin-like growth factor-II transcripts in Wilms' tumour. Nature 1985; 317: 258-260.
17. Haselbacher GK, Irminger JC, Zapf J, Ziegler WH, Humbel RE. Insulin- like growth factor II in human adrenal pheochromocytomas and Wilms tumors: expression at the mRNA and protein level. Proc Natl Acad Sci U S A 1987; 84: 1104-1106.
18. Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F, Le Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1994; 78: 1444-1453.
19. Lambert S, Vivario J, Boniver J, Gol-Winkler R. Abnormal expression and structural modification of the insulin-like growth-factor-II gene in human colorectal tumors. Int J Cancer 1990; 46: 405-410.
20. Murphy SK, Huang Z, Wen Y, Spillman MA, Whitaker RS, Simel LR, Nichols TD, Marks JR, Berchuck A. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res 2006; 4: 283-292.
21. Cariani E, Seurin D, Lasserre C, Franco D, Binoux M, Brechot C. Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis. J Hepatol 1990; 11: 226-231.
22. d'Arville CN, Nouri-Aria KT, Johnson P, Williams R. Regulation of insulin-like growth factor II gene expression by hepatitis B virus in hepatocellular carcinoma. Hepatology 1991; 13: 310-315.
23. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 1995; 11: 221-229.
24. Ron D, Powers AC, Pandian MR, Godine JE, Axelrod L. Increased insulin-like growth factor II production and consequent suppression of growth hormone secretion: a dual mechanism for tumor-induced hypoglycemia. J Clin Endocrinol Metab 1989; 68: 701-706.
25. Fountoulakis EN, Papadaki E, Panagiotaki I, Giannikaki E, Lagoudianakis G, Bizakis J. Primary haemangiopericytoma of the parapharyngeal space: an unusual tumour and review of the literature. Acta Otorhinolaryngol Ital 2011; 31: 194-198.
26. Catalano PJ, Brandwein M, Shah DK, et al. Sinonasal hemangiopericytomas: a clinicopathologic and immunohistochemical study of seven cases. Head Neck 1996; 18: 42-53.
27. Chhieng D, Cohen JM, Waisman J, et al. Fine-needle aspiration cytology of hemangiopericytoma: A report of five cases. Cancer 1999; 87: 190-195.
28. Miraki-Moud F, Grossman AB, Besser M, Monson JP & Camacho-Hubner C. A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia. Journal of Clinical Endocrinology and Metabolism 2005; 90: 3819-3823.
29. Zalinski S, Goumard C, Scatton O, Terris B, Plantier F, Dupin N, Soubrane O. Liver recurrence of a subcutaneous temporal hemangiopericytoma: the index case. J Gastrointest Surg 2009; 13: 1155-1159.
30. Spitz FR, Bouvet M, Pisters PW, et al. Hemangiopericytoma: a 20-year single-institution experience. Ann Surg Oncol 1998; 5: 350-355.
31. Espat NJ, Lewis JJ, Leung D, et al. Conventional hemangiopericytoma. Modern analysis of outcome. Cancer 2002; 95: 1746-1751.
32. Park MS, Araujo DM. New insights into the hemangiopericytoma/solitary fibrous tumor spectrum of tumors. Current Opinion in Oncology 2009; 21: 327-331.
33. Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery 2008; 63: 720-727.
34. Park MS, Lazar AJ, Trent JC, et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/solitary fibrous tumor: an updated analysis [abstract #35064]. In: 14th Connective Tissue Oncologic Society Annual Meeting; 13-15 November 2008; London.
35. Mathieu V, Nève ND, Le Mercier M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human gioblastoma orthotopic xenograft model. Neoplasia 2008; 10: 1383-1392.